These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9378470)

  • 1. Antisense therapy for lymphomas.
    Cotter FE
    Hematol Oncol; 1997 Feb; 15(1):3-11. PubMed ID: 9378470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense therapy of hematologic malignancies.
    Cotter FE
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):9-14. PubMed ID: 10530711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense strategy in hematological malignancies.
    Warzocha K
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model.
    Smith JB; Wickstrom E
    J Natl Cancer Inst; 1998 Aug; 90(15):1146-54. PubMed ID: 9701364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 antisense therapy in B-cell malignancies.
    Chanan-Khan A
    Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 antisense in the treatment of human malignancies: a delusion in targeted therapy.
    Gjertsen BT; Bredholt T; Anensen N; Vintermyr OK
    Curr Pharm Biotechnol; 2007 Dec; 8(6):373-81. PubMed ID: 18289046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for the therapeutic use of antisense oligonucleotides in malignant lymphomas.
    Magrath IT
    Ann Oncol; 1994; 5 Suppl 1():67-70. PubMed ID: 8172821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
    van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
    Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
    Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Bcl-2 antisense therapy for lymphomas.
    Cotter FE; Waters J; Cunningham D
    Biochim Biophys Acta; 1999 Dec; 1489(1):97-106. PubMed ID: 10807000
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice.
    Schlagbauer-Wadl H; Klosner G; Heere-Ress E; Waltering S; Moll I; Wolff K; Pehamberger H; Jansen B
    J Invest Dermatol; 2000 Apr; 114(4):725-30. PubMed ID: 10733680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
    Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
    J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on antisense therapy for the prevention of restenosis.
    Kipshidze N; Moses J; Shankar LR; Leon M
    Curr Opin Mol Ther; 2001 Jun; 3(3):265-77. PubMed ID: 11497351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
    Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS
    Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense therapy for angioplasty restenosis. Some critical considerations.
    Bennett MR; Schwartz SM
    Circulation; 1995 Oct; 92(7):1981-93. PubMed ID: 7671381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.